Risers & Fallers: Centamin, Conroy Gold, DP Poland, Essenden, Premaitha, Tavistock


The following are some of the major news-driven share price changes as at 1.30pm.


Premaitha Health (LON:NIPT), up 35.6%. The non-invasive pre-natal test (NIPT) specialist has been chosen by the St George’s University Hospitals NHS Foundation Trust to provide its IONA test product over a three-year period, with the option to roll-over the contract annually.

Centamin (LON:CEY), up 15.7%. Full-year results gave the shares a boost. Output in 2014 was up 6% at 377,261 ounces of gold; 128,115 ounces were produced in the final quarter. This year production is expected to grow to 420,000 at a cash cost of U$700 an ounce or an all in sustaining cash cost of US$950 an ounce.

Essenden (LON:ESS), up 14.6%. The company said on Friday it has received a preliminary bid approach from a private equity firm. The bowling alley operator said in its results statement on 12 March that it has now reached a point where it is appropriate to examine a range of strategic options that could further enhance shareholder value given recent and potential corporate activity in the bowling sector.


Tavistock Investments (LON:TAVI), down 7.9%. Interim results from the financial services group failed to impress. Loss before tax widened to £343,000 from £246,000 the year before.

DP Poland (LON:DPP), down 6.3%. Underlying losses before exceptional items in 2014 narrowed to £2.41mln from £2.84mln in 2013, with the company putting in a strong finish to the year, with EBITDA for the retail estate positive in each of the final three months of the year.

Conroy Gold & Natural Resources (LON:CGNR), down 6.3%. In-fill drilling at its Clontibret asset in Ireland encountered high grade gold, with grades of 25.29 grams per tonne (g/t) over one 2.5 metre span, and 22.37 g/t over a one metre stretch elsewhere.


Following are some of the major news-driven price changes as at 11.15am.


Immedia (LON:IME), up 21.2%. The shares advanced 3.5p to 20p after a bit of share shuffling by members of the Horrocks family.

Metal Tiger (LON:MTR), up 20.8%. The natural resources investment firm is now able to self-finance its activities, it told investors.

Silence Therapeutics (LON:SLN), up 17.9%. The company’s lead drug candidate has shown early signs of efficacy when used in combination with traditional chemotherapy to treat people with terminal pancreatic cancer.


Karelian Diamond Resources (LON:KDR), down 16.4%. Investors banking profits after Friday’s stonking rise, which was sparked by the discovery of a potential new diamond source in Finland.

Europa Oil & Gas (LON:EOG), down 11.9%. The Kiln Lane-1 well on licence PEDL 181 in north-east Lincolnshire, has been plugged and abandoned. Europa is operator of, and has a 50% working interest in, PEDL 181, which covers an area of over 540 square kilometres in the East Midlands Petroleum Province. Egdon Resources and Celtique Energie Petroleum each have a 25% interest in the licence.

ScS Group (LON:SCS), down 9.7%. Furniture and floorings seller disappointed with its first set of results since listing at the end of January. It made an underlying loss of £3.0mln in the 26 weeks to 24 January, versus a loss of £1.3mln a year earlier. The firm cushioned the blow by revealing sales order intake was up 7.5% on a like-for-like basis for the first 33 weeks of the financial year.


Below are some of the major new-driven share price changes as at 9.00am.


Helius Energy (LON:HEGY), up 115.4%. The company announced after the close of trading on Friday that it plans to get shot of its CoRDe business for £12.3mln, delist from AIM and return cash to shareholders.

Challenger Acquisitions (LON:CHAL), up 21.2%. Speculators are still getting on board after the recently-listed investment company announced a co-operation deal last week with Starneth, the firm behind the London Eye. The market value of the company was just £1.1mln when it floated on 19 February; it is now worth £5.1mln.

Verona Pharma (LON:VRP), up 19.6%. Interim results from the respiratory disease specialist’s new RPL554 trial demonstrate excellent drug tolerability even at the highest dose, the company revealed.


Clean Air Power (LON:CAP), down 22.0%. Full-year loss deepened to £6.34mln from £2.00mln in 2013, while revenue fell to £6.76mln from £9.93mln. On the bright side, the dual-fuel engine management software developer has been awarded an additional one year extension to its two-year funded research project with Brunel University London, aimed at developing the next generation of advanced dual-fuel combustion systems.

Spaceandpeople (LON:SAL), down 17.9%. Profits on 2014 slumped to £1.0mln from £2.6mln, and the full-year dividend has been more than halved to 2.0p from 4.1p.

Egdon Resources (LON:EDR), down 15.2%. Drilling at the Kiln Lane-1 exploration well, in which Egdon has a 25% interest, has not produced the results hoped for, and the well has been plugged and abandoned.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



NQ Minerals' David Lenigas focused on restructuring debt and upping profits...

NQ Minerals PLC's (LON:NQMI) David Lenigas speaks to Proactive London's Andrew Scott soon after taking over as chairman at the Australia-focused mining group. Production and exploration plans aside, Lenigas also says they're in advanced talks to replace on more favourable terms all the debt...

3 hours, 1 minute ago

5 min read